Skip Navigation

State-of-the-art facility

Our state-of-the-art facility is designed and built to meet highest FDA and EMA GMP requirements globally.

Alvotech’s primary focus is on safety, compliance, and flexibility. We strive to combine development with clinical and commercial demands for many products and to meet the needs of customers both today and for many years to come.

The treatment of millions of patients around the world will depend on the safe and reliable production of biopharmaceutical medicines.

Strategic location

Alvotech’s fully vertically integrated biologics manufacturing facility is located at the very heart of Iceland’s capital city, Reykjavik. Iceland offers the ideal environment for this facility, thanks to the country’s strong regulatory system, low energy costs, great talent pool and high-quality standards. Its convenient location between the EU and US places it within easy reach of the rest of the world. In addition, the patent landscape in Iceland allows us additional freedom to operate and support market launch immediately following patent expiry.

Alvotech’s presence at the center of the University of Iceland science park is ideal for fostering close links to academia.

Key facts

State-of-the-art, multiproduct, flexible biomanufacturing facility in Reykjavik Iceland, officially inaugurated in June 2016.

13,278 square meters facility and laboratories.

Aseptic fill and finish lines for vials and prefilled syringes.

GMP manufacturing capacity in a clinical and commercial scale facility.

FDA/EMA GMP standards.

Manufacturing in a patent-free zone can potentially allow for earliest possible market access.

Renewable energy

Alvotech’s focus isn’t solely on the health and well being of patients around the globe, but also on the health of our planet.